Bienvenue au réseau de diffusion sur l'arthrite Arthritis Research Centre of Canada Arthritis Consumer Experts

Call for patient input on SEB etanercept for RA and AS

Stickman with megaphone calling for patient input

Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.

Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading

Le comité ACE publie la neuvième édition de sa fiche-rapport annuelle sur les médicaments contre l’arthrite

French Report Card BannerLe comité ACE (Arthritis Consumer Experts) publie la neuvième édition de sa fiche-rapport annuelle sur les médicaments contre l’arthrite

Bonne ou mauvaise nouvelle pour les Canadiennes et Canadiens atteints d’arthrite, selon la région qu’ils habitent

Le comité ACE (Arthritis Consumer Experts) a publié la neuvième édition de sa fiche-rapport annuelle JointHealth™ sur les médicaments contre l’arthrite. Et le message est clair pour les gouvernements fédéral et provinciaux. L’accès au remboursement des médicaments contre l’arthrite s’est amélioré dans plusieurs provinces canadiennes; toutefois, des inégalités décevantes persistent au chapitre du choix d’un médicament par le médecin et le patient de même que dans l’accès au remboursement des médicaments prescrits par le rhumatologue.

« Grâce à la mobilisation des personnes atteintes d’arthrite et leur rhumatologue, des progrès ont été réalisés dans plusieurs des provinces canadiennes. Nous encourageons les gouvernements fédéral et provinciaux à maintenir leurs engagements envers, selon les estimations, les 600 000 Canadiennes et Canadiens atteints d’une forme d’arthrite auto-immune (polyarthrite rhumatoïde, spondylarthrite axiale, arthrite sporiasique et arthrite juvénile idiopathique) et leur droit de choisir, en collaboration avec leur équipe de soins, le médicament le plus approprié à la biologie de leur maladie, qui peut nettement varier d’un patient à l’autre, » souligne Cheryl Koehn, fondatrice et présidente du comité ACE (Arthritis Consumer Experts).
Continue reading

ACE Releases 9th Annual Arthritis Medications Report Card

Report Card Slide BannerGood news/bad news for Canadians living with arthritis, depending on where they live

Arthritis Consumer Experts (ACE) has released its Ninth Annual JointHealth™ Arthritis Medications Report Card with a clear message to the federal and provincial governments in Canada: Reimbursement access to arthritis medications has improved in many Canadian provinces, however, disappointing inequities remain in patient/physician choice and patient access to reimbursement for the medication prescribed for them by their rheumatologist.

“Thanks to the advocacy efforts of people living with arthritis and their rheumatologists, progress has been made in many Canadian provinces. We encourage the federal and provincial governments to maintain their commitment to the estimated 600,000 Canadians living with a type of autoimmune arthritis – rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis – and their right to choose with their healthcare team the therapy best suited to their disease biology, which is distinctly different from patient to patient,” said Cheryl Koehn, Founder and President, Arthritis Consumer Experts. Continue reading

JointHealth™ Survey on BC PharmaCare policy

Check

JointHealth™ Survey on BC PharmaCare policy

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy.

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy. Gathering your views is very important to the advocacy work that we do on your behalf.

This survey includes 13 questions for people living with arthritis and will take approximately 10 minutes to complete. Your participation will be anonymous and the results will be pooled for analysis to assure your complete privacy. Your responses will in no way impact on your health care or public health insurance coverage.

Thank you for taking the time to participate in this important survey. Your feedback helps us to improve the quality and relevance of Arthritis Consumer Experts’ work.

If you have any questions or comments, please contact us at: feedback@jointhealth.org.

Increased risk of chronic kidney disease in RA patients

A picture of a kidney in human hand

Image courtesy of Anusorn P nacho at FreeDigitalPhotos.net

According to a recent research study, rheumatoid arthritis (RA) patients are at an increased risk for chronic kidney disease (CKD). Along with CKD, researchers also observe increased inflammation within the first year of diagnosis, corticosteroid usage, hypertension, and obesity.

In the study, researchers monitored 813 Mayo Clinic patients with RA and 813 patients without RA for 20 years. They found that RA patients had a one in four chance of developing CKD, while the general public had a one in five chance. “That might not seem like a lot, but in fact that’s quite a big difference, and it has important implications for the course of rheumatoid arthritis and for the management of the disease,” said Dr. Eric Matteson, senior author of the study. Continue reading

Canada’s first measures of performance in treating inflammatory arthritis

Performance meterA team of researchers has developed Canada’s first set of systematic measures for tracking how well or poorly health systems are doing in providing services to people who have inflammatory arthritis (IA), a potentially crippling disease that is on the rise in Canada.

The researchers developed six key measures for gauging access to specialist care and initiation of treatment for people with IA, a disease grouping that includes rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. The work is described in March issue of The Journal of Rheumatology.

People who receive early diagnosis and start of treatment have a better chance of responding well and avoiding permanent joint damage from rheumatoid arthritis (RA), the most common form of IA. There is a growing body of evidence that early detection and treatment are also crucial to good outcomes for people who have other types of IA. Continue reading